Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
In development
Reference number: GID-TA11221
Expected publication date: TBC
Please note that at the request of the company, the timelines for this appraisal have been revised to allow them to develop a robust and comprehensive submission; the appraisal is now anticipated to begin in late November 2023.